Benign prostatic hyperplasia
28
Mar 2022
In March 2022, NHS England and NHS Improvement published the MedTech Funding Mandate (MTFM) policy for 2022/23, which will come into force on April 01, 2022. The MTFM launched in 2021 to support NICE-approved and cost-saving devices, diagnostics, and digital products. Commissioners must fund technologies included in MTFM.
Read more
14
Dec 2021
In early December 2021, NHS Accelerated Access Collaborative announced seven technologies that will be covered by the MedTech Funding Mandate (MTFM) in 2022/23: four for benign prostatic hyperplasia treatment (UroLift, GreenLight XPS, Rezum, and PLASMA system), and three for improving the patient experience during procedures (XprESS multi-sinus dilation system, Thopaz+, and Spectra Optia). Four technologies included in 2021/22 (placental growth factor-based testing, SecurAcath, HeartFlow, and gammaCore) will continue to be supported.
Read more
10
Aug 2021
In July 2021, the Austrian Institute for Health Technology Assessment (AIHTA) published six new decision support documents and one update to a previous decision support document. The assessed topics included percutaneous left ventricular assist devices, liposuction for surgical therapy of lipoedema, triphasic biomaterial for augmentation of the osteoporotic femoral neck, endoscopic plication therapy in patients with gastroesophageal reflux disease (GERD), allogenic bone screw Shark Screw® in patients with hallux valgus or scaphoid fractures/pseudarthroses, and surgical interventions for the treatment of benign prostatic hyperplasia. The updated decision support document concerned implantable bulking agents for fecal incontinence.
Read more
14
May 2021
In late April 2021, the European Network for Health Technology Assessment, EUnetHTA, in partnership with the Austrian Institute for HTA (AIHTA), released a final report on the comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia. Twenty-one minimally invasive surgical treatments for benign prostatic hyperplasia were compared. Newer technologies may offer some advantage over transurethral resection of the prostate by reducing the transfusion requirement.
Read more
09
Sep 2020
At the end of July 2020, the network of European HTA agencies, EUnetHTA, announced the final plan of the project OTCA27 “Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia (BPH).”
Read more